News
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...
Novavax NVAX shares rallied 19.5% in the last trading session to close at $7.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session ...
(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results